(888) 352-RUSH for help arranging an appointment.
Faculty Rank: Professor
Medical or Graduate Education:
University of Illinois College of Medicine at Chicago
Geisinger Medical Center - Internal Medicine
Rush University Medical Center - Medical Oncology
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB. J Thorac Oncol. 2012 2012 Oct 7(10):1618-21. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Fidler MJ, Basu S, Buckingham L, Walters K, McCormack S, Batus M, Coon J 4th, Bonomi P. Anticancer Res. 2012 2012 May;32(5):1705-10. 32(5):1705-10. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Fidler MJ, Shersher DD, Borgia JA, Bonomi P. Ther Adv Med Oncol. 2012 2012 Mar;4(2):51-60. 4(2):51-60. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, et al. Clin Cancer Res. 2012 2012 Jun 1 18(11):3163-9. doi: 10.1158/1078-0432.CCR-11-3090. Epub 2012 Apr 11. Prognostic Significance of Weight Gain During Definitive Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. Sher DJ, Gielda BT, Liptay MJ, Warren WH, Batus M, Fidler MJ, Garg S, Bonomi P. Clin Lung Cancer. 2012 2012 Dec 20. doi:pii: S1525-7304(12)00263-X. 10.1016/j.cllc.2012.10.009. [Epub ahead of print] CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Bradly DP, Gattuso P, Pool M, Basu S, Liptay M, Bonomi P, Buckingham L. Diagn Mol Pathol. 2012 2012 Dec 21(4):207-13. doi: 10.1097/PDM.0b013e31825554b2. Biomarkers of the Insulin-Like Growth Factor Pathway Predict Progression and Outcome in Lung Cancer. Shersher DD, Vercillo MS, Fhied C, Basu S, Rouhi O, Mahon B, Coon JS, Warren WH, Faber LP, Hong E, Bonomi P, Liptay MJ, Borgia JA. Ann Thorac Surg. 2011 Sep 24 Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM J Clin Oncol 2011 Mar 1 29(7):909-16 Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P. J Thorac Oncol. 2011 Jun 6(6):1079-86. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Kim AW, Liptay MJ, Bonomi P, Warren WH, Basu S, Farlow EC, Faber LP. Ann Thorac Surg. 2011 Jul 92(1):233-41; discussion 241-3 Lung cancer: new developments point the way to reduced mortality Bonomi P Oncology (Williston Park) 2011 Jan 25(1):82, 84 Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer Kim AW, Batus M, Myint R, Fidler MJ, Basu S, Bonomi P, Faber LP, Wightman SC, Warren WH, McIntire M, Arvanitis LD, Gattuso P, Xu X, Liptay MJ Lung Cancer 2011 Feb 71(2):186-90 Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers Patel K, Farlow EC, Kim AW, Lee BS, Basu S, Coon JS, Decresce D, Thimothy L, Walters KA, Fhied C, Chang C, Chen SH, Faber LP, Bonomi P, Liptay MJ, Borgia JA Int J Cancer 2010 Sep 7 Weight Gain in Advanced Non-Small-Cell Lung Cancer Patients During Treatment With Split-Course Concurrent Chemoradiotherapy is Associated With Superior Survival Gielda BT, Mehta P, Khan A, Marsh JC, Zusag TW, Warren WH, Fidler MJ, Abrams RA, Bonomi P, Liptay M, Faber LP Int J Radiat Oncol Biol Phys 2010 Oct 5 A multi-analyte serum test for the detection of non-small cell lung cancer Farlow EC, Vercillo MS, Coon JS, Basu S, Kim AW, Faber LP, Warren WH, Bonomi P, Liptay MJ, Borgia JA Br J Cancer 2010 Oct 12 103(8):1221-8 Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer Batus M, Fidler MJ, Bonomi PD Expert Rev Anticancer Ther 2010 Oct 10(10):1589-99 Implications of key trials in advanced nonsmall cell lung cancer Bonomi PD Cancer 2010 Mar 1 116(5):1155-64 Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, Faber LP, Bonomi P, Liptay MJ, Borgia JA Clin Cancer Res 2010 Jul 1 16(13):3452-62 Epidermal growth factor receptor pathway Bonomi P J Thorac Oncol 2010 Dec 5(12 Suppl 6):S470-1 PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J Int J Cancer 2010 Apr 1 126(7):1630-9 Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Kim AW, Faber LP, Warren WH, Basu S, Wightman SC, Weber JA, Bonomi P, Liptay MJ Ann Thorac Surg 2009 Sep 88(3):937-43; discussion 944 Apoptosis Bonomi P J Thorac Oncol 2009 Nov 4(11 Suppl 3):S1061-2 Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer Borgia JA, Basu S, Faber LP, Kim AW, Coon JS, Kaiser-Walters KA, Fhied C, Thomas S, Rouhi O, Warren WH, Bonomi P, Liptay MJ J Thorac Oncol 2009 Mar 4(3):338-47 A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer Gerena-Lewis M, Crawford J, Bonomi P, Maddox AM, Hainsworth J, McCune DE, Shukla R, Zeigler H, Hurtubise P, Chowdhury TR, Fletcher B, Dyehouse K, Ghalie R, Jazieh AR Am J Clin Oncol 2009 Jun 32(3):269-73 Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD J Clin Oncol 2009 Jul 10 27(20):3284-9 Treatment of locally advanced non-small cell lung cancer Fidler MJ, Kim AW, Zusag T, Bonomi P Clin Adv Hematol Oncol 2009 Jul 7(7):455-64, 479-80 Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials Lilenbaum R, Villaflor VM, Langer C, O'Byrne K, O'Brien M, Ross HJ, Socinski M, Oldham FB, Sandilac L, Singer JW, Bonomi P J Thorac Oncol 2009 Jul 4(7):869-74 Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC Clin Lung Cancer 2009 Jul 10(4):252-6 Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE J Clin Oncol 2008 Nov 20 26(33):5407-15 Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer Einhorn LH, Bonomi P, Bunn PA Jr, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS J Thorac Oncol 2008 May 3(5):545-55 Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J Lung Cancer 2008 Jul 61(1):82-90 The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J 4th, Buckingham L, Kaiser K, Basu S, Bonomi P Clin Cancer Res 2008 Apr 1 14(7):2088-94
To watch a brief video of Philip D. Bonomi, MD, click the play button at the lower left corner of the video frame below.
(If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
We have a team of lung cancer specialists — radiation doctors, surgeons, medical oncologists, biochemists, pathologists, radiologists — and we work together.
I’m a strong believer in a Japanese proverb — there’s also an American proverb for this. Japanese say, “None of us is as smart as all of us.” We say, “Two heads are better than one.” So bringing experts together — the surgeons may look at something a little differently than I do. The radiation therapists and I may look at something different than they do. And then together we come and say, “This is what we think is best for this patient.”
Delivering that message from a team of experts at one time is a powerful message. And patients have given us a lot of feedback that they really appreciate it.